HK$53.00
10.62%
Hong Kong, Oct 07, 04:08 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
KYG4790P1037
Symbol
3696

InSilico Medicine Cayman TopCo Target price 2026 - Analyst rating & recommendation

InSilico Medicine Cayman TopCo Classifications & Recommendation

Buy
93%
Hold
7%

InSilico Medicine Cayman TopCo Price Target

Target Price HK$78.54
Price HK$53.00
Potential
Number of Estimates 8
8 Analysts have issued a price target InSilico Medicine Cayman TopCo 2027 . The average InSilico Medicine Cayman TopCo target price is HK$78.54. This is higher than the current stock price. The highest price target is
HK$105.00 98.11%
register free of charge
, the lowest is .
A rating was issued by 14 analysts: 13 Analysts recommend InSilico Medicine Cayman TopCo to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the InSilico Medicine Cayman TopCo stock has an average upside potential 2027 of . Most analysts recommend the InSilico Medicine Cayman TopCo stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion HK$ 0.44 1.44
34.48% 225.70%
EBITDA Margin -92.54% -4.04%
192.18% 95.63%
Net Margin -626.46% -7.00%
3,045.26% 98.88%

10 Analysts have issued a sales forecast InSilico Medicine Cayman TopCo 2026 . The average InSilico Medicine Cayman TopCo sales estimate is

HK$1.4b
unlock
. This is
35.60% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$1.6b 50.01%
unlock
, the lowest is
HK$1.2b 16.07%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$441m 34.48%
2026
HK$1.4b 225.70%
unlock
2027
HK$2.0b 41.38%
unlock
2028
HK$3.3b 62.56%
unlock

10 InSilico Medicine Cayman TopCo Analysts have issued a net profit forecast 2026. The average InSilico Medicine Cayman TopCo net profit estimate is

HK$-101m
unlock
. This is
95.69% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$142m 106.10%
unlock
, the lowest is
HK$-399m 82.93%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$-2.8b 1,960.81%
2026
HK$-101m 96.36%
unlock
2027
HK$387m 484.79%
unlock
2028
HK$2.3b 485.52%
unlock

Net Margin

2025 -626.46% 3,045.26%
2026
-7.00% 98.88%
unlock
2027
19.05% 372.14%
unlock
2028
68.62% 260.21%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ -4.96 -0.17
1,966.67% 96.57%
P/E negative
EV/Sales 20.02

10 Analysts have issued a InSilico Medicine Cayman TopCo forecast for earnings per share. The average InSilico Medicine Cayman TopCo EPS is

HK$-0.17
unlock
. This is
95.95% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$0.25 105.95%
unlock
, the lowest is
HK$-0.69 83.57%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$-4.96 1,966.67%
2026
HK$-0.17 96.57%
unlock
2027
HK$0.67 494.12%
unlock
2028
HK$3.94 488.06%
unlock

P/E ratio

Current
2026
-339.36 2,303.57%
unlock
2027
88.19 125.99%
unlock
2028
15.06 82.92%
unlock

Based on analysts' sales estimates for 2026, the InSilico Medicine Cayman TopCo stock is valued at an EV/Sales of

20.02
unlock
and an P/S ratio of
23.11
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 27.15
2026
20.02 26.26%
unlock
2027
14.16 29.27%
unlock
2028
8.71 38.48%
unlock

P/S ratio

Current
2026
23.11 26.25%
unlock
2027
16.34 29.27%
unlock
2028
10.05 38.48%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today